DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.

Carmen Hidalgo-TenorioDavid VinuesaAntonio PlataPilar Martin DávilaSimona IftimieSergio SequeraBelén LoechesLuis Eduardo Lopez-CortésMari Carmen FariñasConcepción Fernández-RoldanRosario Javier-MartinezPatricia MuñozMaria Del Mar Arenas-MirasFrancisco Javier Martínez-MarcosJose Maria MiróCarmen HerreroElena BereciartuaSamantha E De JesusJuan Pasquau

Published in: Annals of clinical microbiology and antimicrobials (2019)

DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.

Keyphrases

gram negative
healthcare
adverse drug
emergency department
stem cells
escherichia coli
klebsiella pneumoniae
mesenchymal stem cells
cell therapy
combination therapy